PBI sponsored research at the University of Texas at San Antonio has demonstrated that PBI-05204 leads to a marked reduction in neuroinflammtion in brain microglial cells in vitro.

Importantly, when fed to mice orally the PBI drug also produces a significant reduction in accumulation of beta-amyloid plaques within the brains of specifically bred transgenic mice that develop Alzheimer’s-like disease. Taken together ,these recent findings suggest that further exploration of the utility of PBI-05204 for neurodegenerative diseases like Alzheimer’s is warranted.